Dr. Jamie Hardy: The Lifestyle Pharmacist

MARCH 6, 2024

Incorporating Healthy Habits In honor of Women’s History Month, let’s prioritize healthy habits that empower women’s well-being. Nutritious Eating: To prioritize heart health and overall well-being, it’s important to incorporate a diet rich in fruits, vegetables, lean proteins, and whole grains.

98

98

Pharmafile

FEBRUARY 7, 2023

This follows an approval from the EMA’s Committee for Medicinal Products for Human Use in December. The drug is already approved in the EU for the treatment of type 2 diabetes as well as chronic kidney disease. It has also received regulatory approvals in Britain, Japan and Turkey, as well as the US and now the EU.

Communication 105

Communication 105

Digital Pharmacist

MARCH 19, 2024

Their focus on holistic health and lifestyle-based solutions have contributed to an emphasis on mental health and to recent upticks in organic and wellness trends. Approach to Holistic Health and Wellness Gen Zers favor getting and staying healthy over traditional healthcare visits.

104

104

Pharmaceutical Technology

APRIL 18, 2023

IntelGenx Corp announced that the US Food and Drug Administration (FDA) has approved the company’s Rizafilm VersaFilm new drug application (NDA) for the treatment of acute migraine. Rizafilm, the US market name for Rizaport outside of the US, is administered via an oral soluble film.

FDA 98

FDA 98

STAT

SEPTEMBER 14, 2023

They are also looking at what the survival edge can teach us about further improving the health of Hispanics, who make up nearly one-fifth of the U.S. population, and improving health for the rest of the country as well. Read the rest…

141

141

NF2 BioSolutions

APRIL 17, 2024

This blog post contains all the links to the Avastin Diaries Series so far as well as reflections from Joanne Ward, author of this important series. I wanted to write a few words from both of us. upset the daily diary of family life, but it’s amazing how quickly you get used to it.

69

69

STAT

APRIL 11, 2024

While the sun may not be shining, we will rely on sage advice from the Morning Mayor, who reminded us that every new day should be unwrapped like a precious gift. As always, you are invited to join us. So while you tug on the ribbon, we will brew another cup of stimulation. Our choice today is toasted coconut.

Chemotherapy 80

Chemotherapy Immunization 80

STAT

OCTOBER 19, 2023

Having shed its consumer division, the British drug giant is writing a new chapter as a pure-play biopharma company dedicated to the prevention, as well as treatment, of disease. “The answer can’t be sort of flinging science over the airwaves and saying ‘trust us,’ because people don’t.

Vaccines 112

Vaccines 112

Pharmafile

JANUARY 27, 2023

The FDA is calling on the US Congress to work with them on a new regulatory pathway for cannabidiol (CBD). CBD is the non-psychoactive ingredient from the cannabis plant generally considered to have wellness properties. According to the FDA, there have been some safety concerns around CBD, especially with its long-term use.

FDA 88

FDA Communication 88

STAT

FEBRUARY 7, 2024

The middle of the week is upon us. Meanwhile, do keep us in mind if you hear anything interesting. Rise and shine, everyone. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? Consider the alternatives, if you must. And what better way to make the time fly than to keep busy.

Insurance 96

Insurance 96

STAT

DECEMBER 4, 2023

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’

FDA 128

FDA Vaccines 128

STAT

MAY 2, 2023

There was (and continues to be) a desperate hunger for definitive studies telling us how well specific measures would work, with specific publics, in specific settings, for specific strains of the novel and changing virus.

Vaccines 134

Vaccines 134

STAT

OCTOBER 6, 2023

If the Covid-19 pandemic has shown us one thing, it is how little we really know about how the human immune system works. Decoding and harnessing the power of the human immune system is one of the great frontiers of biomedicine.

Immunization 134

Immunization Vaccines 134

Pharmaceutical Technology

MAY 1, 2023

Astellas Pharma has entered into a definitive agreement to buy US-based biopharmaceutical company Iveric bio, in a deal valued at nearly $5.9bn. Under the deal terms, the company, through Astellas US Holding’s wholly owned subsidiary Berry Merger Sub, will acquire all the outstanding Iveric Bio shares for $40.00 in cash for each share.

FDA 111

FDA 111

OctariusRx

JANUARY 8, 2024

In this week’s newsletter, we answer questions related to management for GLP-1s perioperatively and provide our clients with the most recent guidance from the American Society of Anesthesiologists (ASA), as well as the American Gastroenterological Association (AGA). Let us help you enhance patient safety.

68

68

PharmExec

JULY 25, 2023

FDA stresses facility only responsible for 8% of total US hospital consumption for sterile injectable drug market, as well as the need for a reliable drug supply chain.

FDA 52

FDA Hospitals 52

European Pharmaceutical Review

APRIL 29, 2024

The US Food and Drug Administration (FDA) has approved the adeno-associated virus (AAV)-based gene therapy BEQVEZ (fidanacogene elaparvovec-dzkt) for certain adults with haemophilia B. Pfizer stated that the gene therapy enabled sustained bleed protection, “potentially avoiding years of treatment burden with prophylaxis for many patients”.

FDA 76

FDA 76

STAT

DECEMBER 19, 2023

As for us, we are as busy as ever hunting and gathering items of interest. So join us as we hoist the ever-present cup of stimulation — our choice today is gingerbread — and attack the fast-growing to-do list. We trust you have your own busy agendas.

97

97

pharmaphorum

AUGUST 24, 2021

Digital health startup Breathe Well-being has raised $5.5 million in first-round financing, which it will use to scale up its clinical tool that it says helps people “prevent, manage and reverse type 2 diabetes.” Moreover, Breathe Well-being claims users lose an average of 5.5kg after a 16-week programme.

125

125

STAT

NOVEMBER 16, 2023

And what pairs well with a biotech downturn? Our colleague Casey Ross joins us to tell the bombshell story of how the nation’s largest health insurer used a computer algorithm to deny patient care and boost its profitability. Who polices algorithms? How would you name the first approved CRISPR medicine?

Insurance 77

Insurance Patient Care 77

European Pharmaceutical Review

NOVEMBER 2, 2023

The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). Stelara biosimilars in the US market The first Stelara biosimilars are expected to enter the US market in 2025. “We US sales of Stelara totalled $6.4

FDA 90

FDA 90

Pharmafile

SEPTEMBER 26, 2023

This financing was co-led by new US investors Canaan and Alpha Wave, as well as including participation from the Global BioAccess Fund and existing investor Novo Holdings. Acesion Pharma has announced that it has closed an oversubscribed €45m series B financing round.

58

58

Pharmaceutical Technology

JUNE 27, 2022

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for its CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel) to treat relapsed or refractory large B-cell lymphoma (LBCL) in adult patients.

FDA 105

FDA 105

STAT

JANUARY 19, 2024

My time was packed with the usual mix of requests from potential, current, and former clients as well as investors to discuss search projects, and of course the meeting requests from potential candidates. There was still plenty for us to do, and we’ve had some really great placements, but it was slower than the prior year.

90

90

European Pharmaceutical Review

MAY 3, 2024

AstraZeneca stated that Calquence is approved for chronic lymphocytic leukaemia and small lymphocytic lymphoma in the US. In the EU, the treatment is authorised for chronic lymphocytic leukaemia as well as other countries. This include chronic lymphocytic leukaemia and diffuse large B-cell lymphoma.

52

52

STAT

OCTOBER 19, 2022

” But when vaccines to prevent the disease were developed, those same leaders pushed low and middle-income countries to the back of the queue, outbidding poorer countries, as well as COVAX, a worldwide initiative developed to achieve equitable vaccine access, to secure vaccines for themselves.

Vaccines 119

Vaccines Pharmaceutical Companies Pharmaceutical Companies 119

STAT

SEPTEMBER 20, 2023

The middle of the week is upon us. Meanwhile, do keep us in mind if you hear anything interesting. … As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding pharmacies, spas and wellness centers around the U.S. Rise and shine, everyone. Have heart, though.

Compounding 78

Compounding Compounding Pharmacies FDA 78

The Guardian - Pharmaceutical Industry

SEPTEMBER 21, 2023

Competition watchdog probes claims of profiteering by US drugmaker in country where tuberculosis is biggest killer South Africa’s Competition Commission will investigate the American drugmaker Johnson & Johnson for the high price it has been charging for the tuberculosis medicine bedaquiline, as well as for extending its 20-year patent until 2027 (..)

84

84

Pharmaceutical Technology

MARCH 2, 2023

The US Food and Drug Administration (FDA) has approved Reata Pharmaceuticals ’ oral, once-daily medication SKYCLARYS (omaveloxolone) to treat Friedreich’s ataxia patients. SKYCLARYS is indicated to treat the ultra-rare, inherited neurodegenerative disorder in 16 years and above-aged adults and adolescents in the US.

FDA 105

FDA Labelling 105

European Pharmaceutical Review

MARCH 6, 2024

The US Food and Drug Administration (FDA) has approved the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines.

FDA 91

FDA Dosage Labelling 91

Pharmaceutical Technology

NOVEMBER 2, 2022

Reduction in revenues from Comirnaty outside the US and reduced revenues for some Comirnaty-linked manufacturing works carried out on behalf of BioNTech, Xeljanz and Sutent worldwide were the key drivers that contributed to the revenue decline in Q3 2022. in the third quarter last year, indicating a 6% growth. in the prior-year quarter.

116

116

OctariusRx

DECEMBER 23, 2022

We are thankful for our clients who have been with us for many years, as well as the new partners who joined us in 2022. Their commitment to excellence allows us to provide such exceptional service. We also give thanks to those that support and trust us to take care of them. Contact us for assistance.

79

79

pharmaphorum

OCTOBER 28, 2021

The US looks set to see a big expansion of the country’s COVID-19 vaccination drive, with shots looking likely for children aged five to 11 as well as a fourth dose for adults who are immunocompromised. million COVID-19 cases confirmed in the US in the five to 11 bracket. There have also been about 1.8

Vaccines 98

Vaccines FDA Immunization 98

pharmaphorum

AUGUST 23, 2022

Pfizer and BioNTech have asked the FDA for emergency authorisation of an Omicron-targeted COVID-19 booster vaccine ahead of the planned autumn immunisation campaign in the US. The new version of their Comirnaty vaccine includes mRNA for the spike protein of the wild-type SARS-CoV-2 that first emerged in late 2019, as well as for the BA.4

Vaccines 82

Vaccines FDA 82

Pharmafile

JANUARY 9, 2023

US-based CinCor focuses on the development of novel treatments for resistant and uncontrolled hypertension, as well as to treat chronic kidney disease. AstraZeneca has announced that it is set to acquire the clinical-stage biopharmaceutical company CinCor in a deal worth up to $1.8bn. read more.

77

77

European Pharmaceutical Review

DECEMBER 22, 2023

The company will receive up to an additional $285 million in cash payments upon first commercial sales of bota-vec in the US and EU, as well as for manufacturing technology transfer. Under the agreement, MeiraGTx is to receive $130 million in upfront and near-term milestone payments.

93

93

Pharmaceutical Technology

JUNE 8, 2023

The US Food Drug Administration (FDA) has granted orphan drug designation to DTx Pharma’s investigational DTx-1252 for the treatment of Charcot-Marie-Tooth disease Type 1A (CMT1A). CMT1A is a progressive neuromuscular autosomal-dominant disease that leads to life-long loss of muscle function, as well as disability.

FDA 98

FDA 98